Canaccord Adams downgrades Amylin Pharmaceuticals (Nasdaq: AMLN) to Sell. Price target lowered to $8.

Canaccord analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE